# Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients

> **NCT01448174** · PHASE4 · COMPLETED · sponsor: **Poznan University of Medical Sciences** · enrollment: 310 (actual)

## Conditions studied

- Renal Failure Chronic Requiring Hemodialysis
- Metabolic Syndrome
- Diabetes Mellitus Type 2
- Hyperlipidemia

## Interventions

- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT01448174
- **Lead sponsor:** Poznan University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2014-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01448174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01448174, "Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01448174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*